Fresenius SE & Co KGaA (FRE) Given a €62.00 Price Target at Kepler Capital Markets

Kepler Capital Markets set a €62.00 ($72.09) price objective on Fresenius SE & Co KGaA (FRA:FRE) in a research report sent to investors on Monday. The brokerage currently has a buy rating on the stock.

Other analysts have also recently issued reports about the company. Societe Generale set a €72.00 ($83.72) target price on Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Tuesday, November 13th. Deutsche Bank set a €75.00 ($87.21) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Monday, November 26th. Berenberg Bank set a €81.85 ($95.17) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Friday, November 23rd. Sanford C. Bernstein set a €76.50 ($88.95) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Friday, December 7th. Finally, Commerzbank set a €78.00 ($90.70) price target on shares of Fresenius SE & Co KGaA and gave the stock a buy rating in a research note on Friday, December 7th. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of Buy and an average price target of €60.71 ($70.59).

FRA FRE opened at €48.63 ($56.55) on Monday. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02).

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Story: How Does the Quiet Period Work?

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.